Abstract
Lipoprotein lipase (LPL), the rate-limiting enzyme for hydrolysis of plasma lipoprotein triglycerides, is a normal constituent of the arterial wall. We explored whether LPL affects (a) lipoprotein transport across bovine aortic endothelial cells or (b) lipoprotein binding to subendothelial cell matrix (retention). When bovine milk LPL was added to endothelial cell monolayers before addition of 125I-labeled LDL, LDL transport across the monolayers was unchanged; but, at all concentrations of LDL tested (1-100 micrograms), LDL retention by the monolayers increased more than fourfold. 125I-labeled LDL binding to extracellular matrix increased when LPL was added directly to the matrix or was added to the basolateral side of the endothelial cell monolayers. Increased LDL binding required the presence of LPL and was not associated with LDL aggregation. LPL also increased VLDL, but not HDL, retention. Monoclonal anti-LPL IgG decreased both VLDL and LDL retention in the presence of LPL. Lipoprotein transport across the monolayers increased during hydrolysis of VLDL triglyceride (TG). In the presence of LPL and VLDL, VLDL transport across the monolayers increased 18% and LDL transport increased 37%. High molar concentrations of oleic acid to bovine serum albumin (3:1) in the medium increased VLDL transport approximately 30%. LDL transport increased 42% when oleic acid was added to the media. Therefore, LPL primarily increased retention of LDL and VLDL. A less remarkable increase in lipoprotein transport was found during hydrolysis of TG-containing lipoproteins. We hypothesize that LPL-mediated VLDL and LDL retention within the arterial wall potentiates conversion of these lipoproteins to more atherogenic forms.
Introduction
Atherosclerosis, the underlying cause of most cardiovascular diseases, begins with the accumulation of cholesterol-rich lipoproteins within the intima of large arteries. The "response-to-retention" hypothesis suggests that the subendothelial entrapment of low-density lipoprotein (LDL) is the initiating event in plaque formation. Once trapped, LDL undergoes modifications, such as oxidation, which trigger an inflammatory response and the recruitment of macrophages.
Lipoprotein lipase (LPL) is a key enzyme in lipid metabolism, traditionally associated with the hydrolysis of triglycerides in chylomicrons and very-low-density lipoproteins (VLDL) at the capillary endothelium. However, LPL is also synthesized locally within the arterial wall by macrophages and smooth muscle cells. Clinical observations have noted a correlation between arterial LPL levels and the severity of atherosclerotic lesions, yet the precise mechanism by which LPL promotes atherogenesis has remained unclear. This study aims to determine if LPL enhances the transport of lipoproteins across the endothelial barrier or if it primarily functions to increase their retention within the subendothelial matrix.
Methods
An in vitro model of the arterial wall was constructed using bovine aortic endothelial cells grown on semipermeable polycarbonate filters. This setup allowed for the separate measurement of apical-to-basolateral transport (mimicking the movement from blood into the artery wall) and retention within the subendothelial matrix. Purified bovine milk LPL was added to the cell cultures, and radioactively labeled lipoproteins ($^{125}$I-LDL, $^{131}$I-VLDL, and $^{125}$I-HDL) were used to track movement and binding. Retention was quantified by measuring the radioactivity released from the matrix using a heparin wash. Gel electrophoresis was employed to ensure that LPL-mediated retention was not due to simple particle aggregation.
Results
The experimental results strongly support the role of LPL as a bridging molecule that facilitates the retention of atherogenic lipoproteins. When LPL was added to the endothelial cell monolayers, it did not significantly increase the rate of LDL transport from the apical side to the basolateral side. This suggests that LPL does not fundamentally alter the permeability of the endothelial tight junctions or the rate of transcytosis for LDL particles.
However, the impact on retention was dramatic. As illustrated in Figure 2, while the net transport of LDL across the monolayer remained largely unchanged (Panel A), the amount of LDL bound to the subendothelial matrix was significantly higher in the presence of LPL (Panel B). This increase was consistent across a wide range of LDL concentrations (1-100 µg/ml), indicating that the LPL-mediated trapping mechanism is highly efficient even at lower physiological levels of LDL.
The study also distinguished between the physical presence of the LPL protein and its enzymatic activity. Figure 6 highlights that while the products of triglyceride hydrolysis, such as oleic acid, can moderately increase the transport of LDL, they do not contribute to retention.
In contrast, the binding of LPL itself to the matrix (Bound LPL) resulted in a massive percent increase in retention (Figure 6, Panel B). The specificity of this interaction was further demonstrated by the use of monoclonal antibodies against LPL, which successfully blocked the bridging effect and reduced LDL retention by over 60%. Importantly, this mechanism appears selective for atherogenic lipoproteins like LDL and VLDL, as HDL retention remained unchanged regardless of LPL presence.
Discussion
The findings presented here provide a compelling mechanistic link between LPL and the early stages of atherosclerosis. By acting as a molecular bridge between lipoproteins and the heparan sulfate proteoglycans of the extracellular matrix, LPL effectively "anchors" LDL and VLDL within the arterial wall. This anchoring effect is independent of LDL aggregation, a process previously thought to be necessary for entrapment.
The distinction between transport and retention is crucial. While increased endothelial permeability (transport) allows more LDL to enter the arterial wall, it is the retention that determines how long those particles remain there to undergo pathogenic modifications. LPL's ability to selectively trap "bad" cholesterol while sparing "good" cholesterol (HDL) aligns with its known pro-atherogenic associations.
The limitations of this study include its reliance on an in vitro bovine model, which may not perfectly replicate the hemodynamic forces and cellular complexity of the human vasculature. Nevertheless, the isolation of the LPL-mediated retention mechanism provides a clear target for future therapeutic interventions. Strategies aimed at disrupting the LPL-matrix or LPL-lipoprotein interface could potentially reduce the accumulation of cholesterol in the arterial wall and slow the progression of heart disease.
Summary updated